Functional expression of TRAIL by lymphoid and myeloid tumour cells

British Journal of Haematology

Volumn 106, Issue 3, 1999, Pages 827-832

  Zhao, Shourong ^a   Asgary, Zahra ^a   Wang, Yan ^a   Goodwin, Raymond ^b   Andreeff, Michael ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

Apoptosis; Fas; Immunosurveillance; Leukaemia; Lymphoma

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; FAS LIGAND PROTEIN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032846783     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01630.x     Document Type: Article

References (33)

1. Bettinardi, A., Brugnoni, D., Quiros-Roldan, E., Malagoli, A., La Grutta, S., Correrea, A. & Notarangelo, L.D. (1997) Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood, 89, 902-909.
2. Clodi, H., Asgary, Z., Zhao, S., Kliche, K.O., Cabanillas, F., Andreeff, M. & Younes, A. (1998) Coexpression of CD40 and CD40 ligand in B cell lymphoma cells. British Journal of Haematology, 103, 270-275.
3. Degli-Eesposti, M.A., Dougall, W.C., Smolak, P.J., Waugh, J.Y., Smith, C.A. & Goodwin, R.G. (1997a) The novel receptor TRAIL-R4 induces NF-Kappa-B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 7, 813-820.
4. Degli-Eesposti, M.A., Smolak, P.J., Walczak, H., Waugh, J., Huang, C.P., Dubose, R.F., Goodwin, R.G. & Smith, C.A. (1997b) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. Journal of Experimental Medicine, 186, 1165-1170.
5. Drappa, J., Vaishnaw, A.K., Sullivan, K.E., Chu, J.L. & Elkon, K.B. (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. New England Journal of Medicine, 335, 1643-1649.
6. Golstein, P. (1997) Cell death: TRAIL and its receptors. Current Biology, 7, R750-R753.
7. Griffith, T.S. & Lynch, D.H. (1998) TRAIL: a molecule with multiple receptors and control mechanisms. Current Opinion in Immunology, 10, 559-563.
8. Gura, T. (1997) How TRAIL kills cancer cells, but not normal cells. Science, 277, 768.
9. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J.C. & Tschopp, J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science, 274, 1363-1366.
10. Jeremias, L. Herr, I., Boehler, T. & Debatin, K.M. (1998) Trail/Apo-2-ligand-induced apoptosis in human T cells. European Journal of Immunology, 28, 143-152.
11. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H. & Golstein, P. (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science, 265, 528-530.
12. Lee, R.K., Spielman, J., Zhao, D.Y., Olsen, K.J. & Podack, E.R. (1996) Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-adivated killer cells. Journal of Immunology, 157, 1919-1925.
13. Marsters, S.A., Pitti, R.M., Donahue, C.J., Ruppert, S., Bauer, K.D. & Ashkenazi, A. (1996) Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Current Biology, 6, 750-752.
14. Marsters, S.A., Sheridan, J.P., Pitti, R.M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A.D., Godowski, P. & Ashkenazi, A. (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Current Biology, 7, 1003-1006.
15. Nagata, S. (1996) Fas ligand and immune evasion. Nature Medicine, 2, 1306-1307.
16. Nagata, S. (1997) Apoptosis by death factor. Cell, 88, 355-365.
17. Nagata, S. & Golstein, P. (1995) The Fas death factor. Science, 267, 1449-1456.
18. Nagata, S. & Suda, T. (1995) Fas and Fas ligand: Ipr and gld mutations. Immunology Today, 16, 39-43.
19. O'Connell, J., O'Sullivan, C.G., Collins, J.K. & Shanaham, F. (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. Journal of Experimental Medicine, 184, 1075-1082.
20. Pan, G.H., Ni, J., Wei, Y.F., Yu, G.L., Gentz, R. & Dixit, V.M. (1997a) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815-818.
21. Pan, G.H., Orourke, K., Chinniayan, A.M., Gentz, R., Ebner, R., Ni, J. & Dixit, V.M. (1997b) The receptor for the cytotoxic ligand TRAIL. Science, 276, 111-113.
22. Pitti, R.M., Marsters, S.A., Ruppert, S., Donahue, C.J., Moore, A. & Ashkenazi, A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry, 271, 12687-12690.
23. Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fischer, A. & de Villartay, J.P. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 268, 1347-1349.
24. Sheridan, J.P., Marsters, S.A., Pitti, R.M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C.L., Baker, K., Wood, W.I., Goddard, A.D., Godowski, P. & Ashkenazi, A. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277, 818-821.
25. Snell, V., Clodi, K., Zhao, S.R., Goodwin, R., Thomas, E.K., Morris, S.W., Kadin, M.E., Cabanillas, F., Andreeff, M. & Younes, A. (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. British Journal of Haematology, 99, 618-624.
26. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T. & Nagata, S. (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. Journal of Experimental Medicine, 186, 2045-2050.
27. Takahashi, T., Tanaka, M., Brannan, C.I., Jenkins, N.A., Copeland, N.G., Suda, T. & Nagata, S. (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell, 76, 969-976.
28. Walczak, H., Degli-Esposti, M.A., Johnson, R.S., Smolak, P.J., Waugh, J.Y., Boiani, N., Timour, M.S., Gerhart, M.J., Schooley, K.A., Smith, C.A., Goodwin, R.G. & Rauch, C.T. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO Journal, 16, 5386-5397.
29. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C. & Lynch, D.H. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-indudng ligand in vivo. Nature Medicine, 7, 157-163.
30. Walker, P.R., Saas, P. & Dietrich, P.Y. (1997) Role of Fas ligand (Cd951) in immune escape: the tumor cell strikes back. Journal of Immunology, 158, 4521-4524.
31. Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.-P., Nicholl, J.K., Sutherland, G.R., Smith, T.D., Rauch, C., Smith, C.A. & Goodwin, R.G. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-682.
32. Younes, A., Snell, V., Consoli, U., Clodi, K., Zhao, S.R., Palmer, J.L., Thomas, E.K., Armitage, R.J. & Andreeff, M. (1998) Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. British Journal of Haematology, 100, 135-141.
33. Younes, A., Zhao, S., Jendiroba, D., Kleine, H.D., Cabanillas, F. & Andreeff, M. (1995) Decreased expressed of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma. Blood, 65, 2813-2816.